Zendal
Zendal Group is dedicated to scientific excellence applied to biotechnology and pharmacy for human and animal healthcare. With over 30 years of achievements, it specializes in research, development, manufacturing, and marketing of biologics, vaccines, pharmaceuticals, and probiotics. The company operates globally, with facilities in Spain and Portugal, and is committed to innovation, sustainability, and One Health principles, integrating human, animal, and environmental health.
Industries
Nr. of Employees
large (251-1000)
Zendal
A Relva s/n. 36410, O Porriño. Pontevedra (Spain)
Products
Vaccines and biologics for human and animal health
Range of biological products and vaccines across viral, bacterial and parasitic targets manufactured for laboratories, multinationals and governments.
Live attenuated tuberculosis vaccine (clinical-stage)
Live attenuated tuberculosis vaccine candidate in late-stage clinical development (Phase 3 reported) intended for neonatal and adolescent/adult immunization strategies.
Vaccines and biologics for human and animal health
Range of biological products and vaccines across viral, bacterial and parasitic targets manufactured for laboratories, multinationals and governments.
Live attenuated tuberculosis vaccine (clinical-stage)
Live attenuated tuberculosis vaccine candidate in late-stage clinical development (Phase 3 reported) intended for neonatal and adolescent/adult immunization strategies.
Services
End-to-end CDMO services including process development, GMP manufacturing, and support through early clinical phases (Phase I/II) up to commercial production.
Research and clinical development services for vaccine candidates, including clinical operations support, documentation management and regulatory submissions.
Development and manufacturing of probiotics for human and veterinary use to pharmaceutical quality standards.
End-to-end CDMO services including process development, GMP manufacturing, and support through early clinical phases (Phase I/II) up to commercial production.
Research and clinical development services for vaccine candidates, including clinical operations support, documentation management and regulatory submissions.
Development and manufacturing of probiotics for human and veterinary use to pharmaceutical quality standards.
Expertise Areas
- Biologics and vaccine manufacturing
- CDMO contract development and manufacturing
- Vaccine platform research and development
- Clinical trial administrative support
Key Technologies
- Upstream and downstream bioprocessing
- Aseptic vial and stick filling
- Lyophilization (freeze-drying)
- Live attenuated vaccine platforms
News & Updates
Zendal received EMA recommendation for its vaccine against EHDREAD in March 2025.
In February 2025, Biofabri and IAVI announced the first vaccinations in the IMAGINE clinical trial for a tuberculosis vaccine candidate.
In January 2025, Zendal supplied 42 million doses of bluetongue vaccine across Europe.
CZ Vaccines is an international benchmark in the development and manufacturing of vaccines for brucellosis.
Zendal has developed a Spanish vaccine against tuberculosis, currently in phase 3 clinical trials.
An article about probiotics and their importance in health, published in May 2023.
Zendal received EMA recommendation for its vaccine against EHDREAD in March 2025.
In February 2025, Biofabri and IAVI announced the first vaccinations in the IMAGINE clinical trial for a tuberculosis vaccine candidate.
In January 2025, Zendal supplied 42 million doses of bluetongue vaccine across Europe.
CZ Vaccines is an international benchmark in the development and manufacturing of vaccines for brucellosis.
Zendal has developed a Spanish vaccine against tuberculosis, currently in phase 3 clinical trials.
An article about probiotics and their importance in health, published in May 2023.